

Balancing the Effectiveness and Costs of Immune Checkpoint Inhibitors in Advanced Cancer

Michael McKenna

School of Medicine, Trinity College, University of Dublin, Ireland

Abstract

Conventional cancer therapeutics, while having transformed the survival of patients diagnosed with early stage cancer, have failed to produce similar results in patients diagnosed with more advanced cancer. It is for this reason that the arrival of immunotherapy has generated such a visceral interest in the field of oncology. Labelled 'Breakthrough of the Year' by Science in 2013, the field of immunotherapy has continued to grow exponentially, and promising preclinical results have translated into efficacious results in clinical trials, particularly in patients with end-stage disease. This has culminated in an ever-growing list of approvals for agents which have been designed to harness the power of the immune system. Immune checkpoint inhibitors in particular are regarded as potent new tools in the cancer therapeutics arsenal and have produced remarkable results in clinical trials in various cancer types. However, in the context of their increasing use in combination therapy and their remarkably high cost:benefit ratio, it must be asked whether these immune checkpoint inhibitors are a realistic solution to an ever increasing cancer burden. Is their price just a little too steep to pay?

Advanced cancer survival

Improvements in treatment modalities have transformed the survival rates of patients diagnosed with cancer. Cancer survival has more than doubled over the past 40 years (Cancer Research UK 2017a), with cancer mortality predicted to continue to decrease for the majority of cancer types over the next two decades (Smittenaar et al 2016). Unfortunately, these prominent improvements in survival have not translated across to advanced cancers, with stage IV metastatic disease continuing to show poor survival at 1 and 5 years post-diagnosis. Pancreatic cancer, which has the worst prognosis of all cancer types, has shown no improvement in survival in the past 40 years, with only

3% of patients surviving to 5 years (Cancer Research UK 2017b). 5-year survival statistics for stage IV lung cancer have been notoriously difficult to assess because such a small proportion of patients survive beyond 2 years (Cancer Research UK 2017c), while current 5-year survival statistics for Stage IV ovarian and bowel cancer are 4% and 7-8% respectively (Cancer Research UK 2017d-e). The discrepancy in outcomes on the basis of cancer stage is especially prominent when one looks at breast cancer in females, where 99% of Stage I patients will be alive at 5 years compared to 15% of Stage IV patients, and melanoma in males, where 100% of Stage I patients are alive at 5 years compared to 8% of Stage IV patients (Cancer Research UK 2017f-g).

Immunotherapy

Immunotherapy has emerged as potential lifeline for terminal cancer patients and has generated significant interest in both the academic community and the media. In contrast to previous treatment modalities which attacked tumours directly, immunotherapy indirectly targets tumours by potentiating the immune response the body generates against the cancer (Couzin-Frankel 2013). With a history dating back to Virchow's observation of immune infiltrates in tumours and Coley's use of bacteria solutions to generate inflammatory responses against cancer, immunotherapy is currently experiencing a renaissance and multiple types are in development. Promising results have been seen to date with dendritic cell therapy (Schumacher et al 2015), oncolytic virus therapy (Banchereau et al 2005), neo-antigen vaccination (Parato et al 2005) and adoptive cell transfer (Rosenburg et al 2008). However, immune checkpoint inhibitors have emerged as the leading candidates in clinical immunotherapy.

Immune checkpoint inhibitors

The immune system is capable of recognising and

destroying cancer cells, but its activity is moderated by a series of ligand-inhibitory receptor interactions known as immune checkpoints (Pardoll 2012). The purpose of these checkpoints is to maintain self-tolerance and limit collateral damage to normal tissues generated by the immune response. However they can be hijacked by tumours as a means of escaping destruction and ensuring their own survival (Topalian et al 2015). The two major immune checkpoints – cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) have slightly differing functions (Figure 1). CTLA4 signalling restricts T-cell activity while the immune response is initiated whereas PD1 acts later in the immune response, minimising collateral damage to adjacent tissues during chronic inflammation (Siefker-Radtke et al 2018). Therefore, blockade of these immune checkpoints could intensify the T-cell response and result in tumour eradication.

Efficacy of immune checkpoint inhibitors as monotherapies

The benefits from immune checkpoint inhibitors have been unprecedented in the history of terminal cancer treatment. Their promise was first elucidated with Ipilimumab, a CTLA-4 inhibitor, in metastatic melanoma, a cancer with a notoriously poor prognosis. Ipilimumab treatment resulted in a median overall survival of 10 months compared to a glycoprotein 100 peptide vaccine alternative, which produced a median survival of 6.4 months (Hodi et al 2010). Nivolumab, a PD-1 inhibitor, produced similar results in melanoma, with confirmed objective responses seen in 31.7% compared to 10.6% of the investigators choice-of-

chemotherapy (Weber et al 2015). Nivolumab also found utility in NSCLC, with an overall survival rate of 12.2 months compared to 9.4 months in the docetaxel standard-of-care arm (Borghaei et al 2015).

Pembrolizumab, a PD-1 inhibitor similar to Nivolumab, was explored in a wide variety of trials and produced encouraging results in numerous cancer types including NSCLC (Reck et al 2016), melanoma (Robert et al 2015) and urothelial carcinoma (Balar et al 2017a). Pembrolizumab is best known as the first drug in history to receive FDA approval on the basis of a tumour characteristic, receiving approval for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) paediatric and adult solid tumours irrespective of site. Recent focus has shifted to PD-L1 inhibitors, and various agents have produced results comparable to the PD-1 inhibitors. Atezolizumab was the first of these agents to be explored. Promising response rates were seen in a phase II trial of metastatic urothelial carcinoma (Balar et al 2017b) but it ultimately failed to produce prolonged survival in a subsequent phase III trial (Powles et al 2018). However, Atezolizumab found its niche in the Phase III OAK trial, producing more favourable overall survival in NSCLC patients vs docetaxel (Rittmeyer et al 2017). However, to date, no trial has been performed to compare overall survival in NSCLC patients treated with Atezolizumab against those treated with Nivolumab. Results from next-generation PD-L1 inhibitors have been encouraging. The JAVELIN Solid Tumour trial demonstrated potent anti-tumour activity of Avelumab in platinum-refractory metastatic urothelial carcinoma (Patel et al 2018) while the ATLANTIC trial demonstrated a role for Durvalumab




Figure 1: The major immune checkpoints, their functions and how they are targeted

as a third-line or later agent in EGFR-negative NSCLC (Garassino et al 2018).

Resistance to immune checkpoint inhibitors

The problem of resistance to immune checkpoint therapy has begun to emerge as a major limiting factor impeding their effectiveness in monotherapy. While a small proportion of patients maintain a continuous response, two significant subgroups have emerged – those failing to respond from therapy initiation (innate resistance) and those who respond initially but develop resistance over the course of therapy (acquired resistance) (Pitt et al 2016). The causes of resistance are variable and can be broadly divided into 3 main groups – impaired tumour reactive T-cell formation, impaired effector T-cell activation and impaired memory T-cells formation (Jenkins et al 2018) (Figure 2). As such, recent focus has turned towards using immunotherapies in combination therapies for terminal patients.

Combinations of different immune checkpoint inhibitors

Immune checkpoint inhibitors present an exciting avenue for combination therapy, combined either with each other or with alternative forms of therapy. The combinations of different immunotherapies continue to produce promising results, particularly combined Nivolumab-Ipilimumab which was studied first in melanoma. Initially compared against Ipilimumab monotherapy, the combination achieved a higher objective response rate (61% vs 11%) and complete response rate (22% vs 0%), as well as a significant increase in 2-year overall survival (63.8% vs 53.6%) (Postow et al 2015, Hodi et al 2016). Nivolumab-Ipilimumab was also

tested against Nivolumab monotherapy, increasing median progression-free survival at initial analysis (11.5 months vs 6.9 months), accompanied by a slight increase in overall survival (58% vs 52%) at the 3-year follow-up (Larkin et al 2015, Wolchok et al 2017).

The scope of the Nivolumab-Ipilimumab combination continues to spread, showing encouraging results in trials of both non-small cell and small cell lung cancer (Hellman et al 2017, Antonia et al 2016a), metastatic renal cell carcinoma (Hammers et al 2017) and metastatic sarcoma (D'Angelo et al 2018). Combinations of newer generation anti-PD-1 and anti-CTLA-4 antibodies are also beginning to emerge such as durvalumab with tremelimumab, which displayed potent anti-tumour activity in a Phase Ib NSCLC study (Antonia et al 2016b). The potential for the combination of anti-PD-1 therapies with antibodies targeting newly discovered immune checkpoint receptors such as Tim-3 and LAG-3 has been promising to date (Sakuishi et al 2010, Woo et al 2012).

Combinations of immune checkpoint inhibitors with other cancer therapies

Checkpoint inhibitors have also shown promising results in combination with other forms of cancer therapy. Local control and clinical benefit was seen in one study where ipilimumab was combined with stereotactic external-beam radiation therapy (Sundahl et al 2018) while a decreased incidence of brain metastases and favourable survival outcomes were seen in a second study combining either ipilimumab, nivolumab or pembrolizumab with stereotactic radiosurgery (Chen et al 2018). Nivolumab has shown benefit when combined with various chemotherapeutic regimens in NSCLC including gemcitabine/cisplatin, pemetrexed/cisplatin and paclitaxel/carboplatin (Rizvi et al 2016, Kanda et al 2016). While still a relatively new field, checkpoint inhibitors have shown clinical efficacy in early clinical trials with various other agents including anti-angiogenic therapies (Amin et al 2014, Atkins et al 2018), MEK inhibitors (Ribas et al 2015) and BRAF inhibitors (Cooper et al 2014).

Cost-effectiveness of immune checkpoint inhibitors: These promising results have come with a steep price, with immune checkpoint inhibitors rapidly establishing themselves as some of the most expensive therapies available to modern medicine. One study from Switzerland compared the cost-effectiveness




Figure 2: Mechanisms of resistance to immune checkpoint inhibitors

of Nivolumab against Docetaxel for advanced non-squamous NSCLC and found that it was not a cost-effective improvement for patient care, exceeding the willingness-to-pay threshold by almost 78,000 CHF (Matter-Walstra et al 2016). A similar study conducted in Canada found that Nivolumab cost over \$150,000 extra per quality-adjusted life year (QALY) compared to Docetaxel in NSCLC (Goeree et al 2016). An Australian Monte Carlo analysis found that Nivolumab was only considered cost-effective if compared against Ipilimumab for BRAF Wild-Type advanced melanoma and Nivolumab was deemed not to be cost-effective against placebo in a US study of its use in second-line metastatic renal cell carcinoma treatment (Bohensky et al 2016, Sarfaty et al 2018). While the relatively recent emergence of checkpoint inhibitor combination therapy leaves a current shortage of cost-effectiveness analysis available, one US study of the Nivolumab-Ipilimumab combination in first line metastatic melanoma found it was not cost-effective compared to Nivolumab monotherapy (Oh et al 2017).

Trends in cancer incidence and cost

The high costs of these checkpoint inhibitors cannot be ignored, especially in the context of current cancer incidence trends. Cancer incidence in Ireland is projected to grow by 84% in females and 107% in males by 2040 (National Cancer Registry Ireland 2014), mirroring trends in the United Kingdom, where incidence is projected to increase by 35% in females and 55% in males by 2030 (Mistry et al 2011). Almost a quarter of the UK population aged 65 years or older in 2040 will be cancer survivors (Maddams et al 2012). Similar statistics are seen elsewhere in the developed world – increases in age-standardised rates of cancer are seen in Australia in both males and females, while the total projected incidence of cancer in the United States is projected to rise by 45% by 2030 (Australian Institute of Health and Welfare 2012, Smith et al 2009). These trends are not restricted to the developed world; the burden of cancer continues to grow in developing countries as a result of aging populations and they will carry a significant proportion of the increases in cancer incidence, morbidity and mortality by 2030 (Thun et al 2010, Kanavos et al 2006).

This rising cancer burden is accompanied by an ever-increasing cost of cancer care. Between 2010 and 2020, the cost of healthcare will have risen by 39% in the

United States, reaching an annual expenditure of \$173 billion (Mariotto et al 2011). Between 1991 and 2002, the per patient cost of caring for lung, colorectal and breast cancer patients increased by over \$7000, over \$5000 and over \$4000 respectively, and colorectal cancer expenditure alone will have increased by 89% between 2010 and 2020 (Warren et al 2008, Yabroff et al 2008). The average price of cancer drugs per patient per year rose from \$5000-10,000 before 2000 to over \$100,000 in 2012 and cancer drug expenditure will have risen by 50% over the 10-year period from 2010-2020 (Light et al 2013, Prasad et al 2017). Recently developed immune checkpoint inhibitors are likely to only add to this financial burden further. In NSCLC alone, Atezolizumab is estimated to cost a median of \$68,960 per patient, while Pembrolizumab and Nivolumab cost \$83,691 and \$87,575 respectively for a total course of treatment for each patient (Ogale 2018). The Nivolumab-Ipilimumab combination costs substantially higher at \$295,566 per patient and the overall cost of implementing these drugs to tackle metastatic cancer was predicted to cost as high as \$174 billion per annum in America alone (Andrews 2015).

Conclusion

The spiralling cost of cancer care has extended from the healthcare provider to the patient themselves. Conservative estimates show that cancer can cost an average patient €832 per month, with 60% of patients experiencing an annual income reduction of over €16,500 (Irish Cancer Society 2015). The cost of new medications is increasingly recognised as a driving force behind the increasing financial toxicity of a cancer diagnosis and it is difficult to imagine that these new high-cost checkpoint inhibitors will do anything other than increase the burden further, on both the state and the patient. With higher cancer expenditure causing patients to delay or forgo treatment, reduce adherence to cancer treatment and increase their risk of bankruptcy, the question must be asked as to whether these expensive immune checkpoint inhibitors are the right step forward in the fight against terminal cancer.

References

- Andrews, A. (2015) 'Treating with checkpoint inhibitors – figure \$1 million per patient', *American Health & Drug Benefits*, 8(Spec Issue), 9.
- Amin, A., Plimack, ER., Infante, JR., et al. (2014) 'Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)', *The Journal of Clinical Oncology*, 32(15 Suppl), Abstract 5010.
- Antonia, S., López-Martin, JA., Bendell, J., et al. (2016a) 'Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial', *The Lancet Oncology*, 17(7), 883-95.
- Antonia, S., Goldberg, SB., Balmanoukian, A., et al. (2016b) 'Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study', *The Lancet Oncology*, 17(3), 299-308.
- Atkins, MB., Plimack, ER., Puzanov, I., et al. (2018) 'Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial', *The Lancet Oncology*, 19(3), 405-15.
- Australian Institute of Health and Welfare. (2012) *Cancer incidence projections: Australia, 2011 to 2020. Cancer Series no. 66*, Canberra: Australian Institute of Health and Welfare.
- Balar, AV., Castellano, D., O'Donnell, PH., et al. (2017a) 'First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study', *The Lancet Oncology*, 18(11), 1483-92.
- Balar, AV., Galsky, MD., Rosenberg, JE., et al. (2017b) 'Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial', *The Lancet*, 389(10064), 67-76.
- Banchereau, J., Palucka, AK. (2005) 'Dendritic cells as therapeutic vaccines against cancer', *Nature Reviews Immunology*, 5(4), 296-306.
- Bohensky, MA., Pasupathi, K., Gorelik, A., et al. (2016) 'A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia', *Value in Health*. 19(8), 1009-15.
- Borghaei, H., Paz-Ares, L., Horn, L., et al. (2015) 'Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer', *The New England Journal of Medicine*, 373(17), 1627-39.
- Cancer Research UK (2018) *Cancer survival statistics for all cancers combined* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/survival/all-cancers-combined#heading-Zero> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Pancreatic cancer survival statistics* [online]. Available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/survival#heading-Zero> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Lung cancer survival statistics* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival#heading-Three> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Ovarian cancer survival statistics* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/survival#heading-Three> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Bowel cancer survival statistics* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival#heading-Three> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Breast cancer survival statistics* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Three> [accessed 26 Nov 2018]
- Cancer Research UK. (2018) *Skin cancer survival statistics* [online]. available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/skin-cancer/survival#heading-Three> [accessed 26 Nov 2018]
- Chen, L., Douglass, J., Kleimberg, L., et al. (2018) 'Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma', *International Journal of Radiation Oncology, Biology, Physics*, 100(4), 916-25.
- Cooper, ZA., Juneja, VR., Sage, PT., et al. (2014) 'Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade', *Cancer Immunology Research*, 2(7), 643-54.
- Couzin-Frankel, J. (2013) 'Breakthrough of the year 2013, Cancer Immunotherapy', *Science*, 342(6165), 1432-3.
- D'Angelo, SP., Mahoney, MR., Van Tine, BA., et al. (2018) 'Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials', *The Lancet Oncology*, 19(3), 416-26.
- Garassino, MC., Cho, BC., Kim, JH., et al. (2018) 'Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study', *The Lancet Oncology*, doi:10.1016/S1470-2045(18)30144-X [Epub ahead of print]
- Goeree, R., Villeneuve, J., Goeree, J., et al. (2016) 'Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes', *Journal of Medical Economics*, 19(6), 630-44.
- Hammers, HJ., Plimack, ER., Infante, JR., et al. (2017) 'Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study', *The Journal of Clinical Oncology*, 35(34), 3851-8.
- Hellman, MD., Rizvi, NA., Goldman, JW., et al. (2017) 'Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study', *The Lancet Oncology*, 18(1), 31-41
- Hodi, FS., O'Day, SJ., McDermott, DF., et al. (2010) 'Improved survival with ipilimumab in patients with metastatic melanoma', *The New England Journal of Medicine*, 363(8), 711-23.
- Hodi, FS., Chesney, J., Pavlick, AC., et al. (2016) 'Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial'. *The Lancet Oncology*, 17(11), 1558-68.
- Irish Cancer Society. (2015) *The Real Cost of Cancer*, Dublin: Irish Cancer Society.
- Jenkins, RW., Barbie, DA. and Flaherty, KT. (2018) 'Mechanisms of resistance to immune checkpoint inhibitors', *British Journal of Cancer*, 118(1), 9-16.
- Kanavos P. (2006) 'The rising burden of cancer in the developing world', *Annals of Oncology*, 17(Suppl 8), viii15-viii23.
- Kanda, S., Goto, K., Shiraishi, H., et al. (2016) 'Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase 1b study', *Annals of Oncology*, 27(12), 2242-50.
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) 'Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma', *The New England Journal of Medicine*, 373(1), 23-34.

- Light, DW. and Kantarjian, H. (2013) 'Market spiral pricing of cancer drugs', *Cancer*, 119(22), 3900-2.
- Maddams, J., Utley, M. and Møller, H. (2012) 'Projections of cancer prevalence in the United Kingdom, 2010-2040', *British Journal of Cancer*, 107(7), 1195-202.
- Mariotto, AB., Yabroff, KR., Shao, Y., et al. (2011) 'Projections of the cost of cancer care in the United States: 2010-2020', *Journal of the National Cancer Institute*, 103(2), 117-28.
- Matter-Walstra, K., Schwenkglenks, M., Aebi, S., et al. (2016) 'A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing', *Journal of Thoracic Oncology*, 11(11), 1846-55.
- Mistry, M., Parkin, DM., Ahmad, AS., et al. (2011) 'Cancer incidence in the United Kingdom: projections to the year 2030', *British Journal of Cancer*, 105(11), 1795-803.
- National Cancer Registry Ireland. (2014) *Cancer projections for Ireland 2015-2040*, Cork: National Cancer Registry Ireland.
- Ogale, S. (2018) 'Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors'', *Annals of Oncology*, 29(10), 2140.
- Oh, A., Tran, DM., McDowell, LC., et al. (2017) 'Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States', *Journal of Managed Care and Speciality Pharmacy*, 23(6), 653-64.
- Parato, KA., Senger, D., Forsyth, PA., et al. (2005) 'Recent progress in the battle between oncolytic viruses and tumours', *Nature Reviews Cancer*, 5(12), 965-76.
- Pardoll, DM. (2012) 'The blockade of immune checkpoints in cancer immunotherapy', *Nature Reviews Cancer*, 12(4), 252-64.
- Patel, MR., Ellerton, J., Infante, JR., et al. (2018) 'Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial', *The Lancet Oncology*, 19(1), 51-64.
- Pitt, JM., Vétizou, M., Daillère, R., et al. (2016) 'Resistance Mechanism to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors', *Immunity*, 44(6), 1255-69.
- Postow, MA., Chesney, J., Pavlick, AC., et al. (2015) 'Nivolumab and ipilimumab versus ipilimumab in untreated melanoma', *The New England Journal of Medicine*, 372(21), 2006-17.
- Powles, T., Durán, I., van der Heijden, MS., et al. (2018) 'Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial', *The Lancet*, 391(10122), 748-57.
- Prasad, V., De Jesús, K. and Mailankody, S. (2017) 'The high price of anticancer drugs: origins, implications, barriers, solutions', *Nature Reviews Clinical Oncology*, 14(6), 381-90.
- Reck, M., Rodríguez-Abreu, D., Robinson, AG., et al. (2016) 'Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer', *The New England Journal of Medicine*, 375(19), 1823-33.
- Ribas, A., Butler, M., Lutzky, J., et al. (2015) 'Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma', *The Journal of Clinical Oncology*, 33(15 Suppl), Abstract 3003.
- Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. (2017) 'Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial', *The Lancet*, 389(10066), 255-65.
- Rizvi, NA., Hellmann, MD., Brahmer, JR., et al. (2016) 'Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer', *The Journal of Clinical Oncology*, 34(25), 2969-79.
- Robert, C., Schachter, J., Long, GV., et al. (2015) 'Pembrolizumab versus Ipilimumab in Advanced Melanoma', *The New England Journal of Medicine*, 372(26), 2521-32.
- Rosenburg, SA., Restifo, NP., Yang, JC., et al. (2008) 'Adoptive cell transfer: a clinical path to effective cancer immunotherapy', *Nature Reviews Cancer*, 8(4), 299-308.
- Sakuishi, K., Apetoh, L., Sullivan, JM., et al. (2010) 'Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity', *Journal of Experimental Medicine*, 207(20), 2187-94.
- Sarfaty, M., Leshno, M., Gordon, N., et al. (2018) 'Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma', *European Urology*, 73(4), 628-34.
- Schumacher, TN. and Schreiber, RD. (2015) 'Neoantigens in cancer immunotherapy', *Science*, 348(6230), 69-74.
- Siefker-Radtke, A. and Curti, B. (2018) 'Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition', *Nature Reviews Urology*, 15(2), 112-24.
- Smith, BD., Smith, GL., Hurria, A., et al. (2009) 'Future of cancer incidence in the United States: burdens upon an aging, changing nation', *The Journal of Clinical Oncology*, 27(17), 2758-65.
- Smittenaar, CR., Petersen, KA., Stewart, K., et al. (2016) 'Cancer incidence and mortality projections in the UK until 2035', *British Journal of Cancer*, 115(9), 1147-55.
- Sundahl, N., De Wolf, K., Kruse, V., et al. (2018) 'Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma', *International Journal of Radiation Oncology, Biology, Physics*, 100(4), 906-15.
- Thun, MJ., DeLancey, JO., Center, MM., et al. (2010) 'The global burden of cancer: priorities for prevention', *Carcinogenesis*, 31(1), 100-10.
- Topalian, SL., Drake, CG. and Pardoll, DM. (2015) 'Immune checkpoint blockade: a common denominator approach to cancer therapy', *Cancer Cell*, 27(4), 450-61.
- Warren, JL., Yabroff, KR., Meekins, A., et al. (2008) 'Evaluation of trends in the cost of initial cancer treatment', *Journal of the National Cancer Institute*, 100(12), 888-97.
- Weber, JS., D'Angelo, SP., Minor, D., et al. (2015) 'Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial', *The Lancet Oncology*, 16(4), 375-84.
- Wolchok, JD., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) 'Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma', *The New England Journal of Medicine*, 377(14), 1345-56.
- Woo, SR., Turnis, ME., Goldberg, MV., et al. (2012) 'Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape', *Cancer Research*, 72(4), 917-27.
- Yabroff, KR., Mariotto, AB., Feuer, E., et al. (2008) 'Projections of the costs associated with colorectal cancer care in the United States, 2000-2020', *Health Economics*, 17(8), 947-59.